All In Biotech

Drug Trial Radar · NCT06521931

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

A Single-arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Patients With Lymphoma or Solid Tumor

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 6, 2023

Primary completion

Jan 13, 2025

Study completion Jan 13, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with chemotherapy-induced thrombocytopenia (CID). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 prevention? Participants will * Receive subcutaneous injections of PN20 according to weight on the first day of chemotherapy cycle, within 1 hour before the administration of chemotherapy drugs, * Visit the clinic on Day 1 (D1), D2, D3, D4, D5, D8, D11, D13, D15 and D21 for assessment.

Conditions

  • Thrombocytopenia

Interventions

  • PN20Drug

    Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE in single-dose phaseTime frame: Day 1-21 of Cycle 1 (each cycle is 21 days)
  2. The proportion of patients with PLT ≥ 100×10^9/L in multiple-dose phaseTime frame: Day 21 of Cycle 2 (each cycle is 21 days)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Yiyang Central Hospital

    Yiyang, Hunan, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.